Zymergen Announces Pricing of Upsized Initial Public Offering
April 21 2021 - 11:31PM
Zymergen Inc. (“Zymergen”), one of the world’s foremost
biofacturing companies, today announced the pricing of its initial
public offering of 16,130,000 shares of its common stock at a
public offering price of $31.00 per share. In addition, Zymergen
has granted the underwriters a 30-day option to purchase up to an
additional 2,419,500 shares of its common stock at the initial
public offering price, less underwriting discounts and commissions.
Zymergen’s common stock is expected to begin trading on the Nasdaq
Global Select Market on April 22, 2021 under the ticker symbol
“ZY”. The gross proceeds from the offering to Zymergen, before
deducting underwriting discounts and commissions and other offering
expenses payable by Zymergen, are expected to be approximately $500
million, excluding any exercise of the underwriters’ option to
purchase additional shares. The offering is expected to close on
April 26, 2021, subject to the satisfaction of customary closing
conditions.
J.P. Morgan and Goldman Sachs & Co. LLC are acting as lead
book-running managers for the offering. BofA Securities, Cowen and
UBS Investment Bank are acting as book-running managers. Lazard is
acting as co-manager.
The offering is being made only by means of a prospectus, copies
of which may be obtained, when available, from: J.P. Morgan
Securities LLC, Attention: Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717 or by telephone at
866-803-9204 or by email at prospectus-eq_fi@jpmorganchase.com; or
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200
West Street, New York, NY 10282, by telephone at (866) 471-2526 or
by email at prospectus-ny@ny.email.gs.com.
A registration statement relating to the sale of these
securities has been filed with, and declared effective by, the
Securities and Exchange Commission. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy
these securities, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About ZymergenZymergen is a biofacturing
company using biology to reimagine the world. Zymergen partners
with nature to design, develop and manufacture bio-based
breakthrough products that deliver value to customers in a broad
range of industries. A unique combination of biology, chemistry,
software and automation enables the company to design and create
new materials.
Investor ContactNiraj
Javeriinvestors@zymergen.com
Media ContactMike
Dulinmdulin@zymergen.com502-777-2029
Zymergen (NASDAQ:ZY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zymergen (NASDAQ:ZY)
Historical Stock Chart
From Apr 2023 to Apr 2024